Core Viewpoint - The company is expected to see a gradual recovery in sales in the second half of the year, following a rebound in performance after a temporary setback due to a public relations incident in May [1][2] Group 1: Sales Performance - After the public relations incident on May 24, the company's sales were impacted but remain manageable, with a notable recovery in July as some top influencers resumed live streaming the company's products [1] - Data from Jiuqian shows that in July, the company's GMV on Tmall and Douyin increased by 70% and 17% year-on-year, respectively, indicating a positive sales trend [1] - The company ranked 16th in Tmall's beauty category during the 618 shopping festival, up from 12th place in 2024, suggesting a strong market presence [1] Group 2: Product Development and Market Strategy - The company has a well-established research foundation in the collagen field, with a focus on high-quality product offerings that enhance brand recognition [1] - The product matrix includes medical devices, collagen repair products, and targeted series, with the collagen stick serving as a flagship product to stabilize market share [2] - The company is actively enhancing its anti-aging image through increased investment in core products and new product launches, which are expected to drive growth [2] Group 3: Financial Projections - The company is projected to achieve revenues of 6.86 billion, 8.49 billion, and 10.21 billion yuan from 2025 to 2027, with net profits of 2.43 billion, 2.95 billion, and 3.49 billion yuan, respectively [2] - The corresponding price-to-earnings ratios are expected to be 25.2, 20.7, and 17.5 times for the same period, indicating a favorable valuation outlook [2]

Investment Rating - The investment rating for the company is upgraded to "Buy" [2] Core Views - The company is expected to see a gradual recovery in sales in the second half of the year, supported by a rebound in live streaming sales and a stable offline sales network [8] - The company has a strong foundation in recombinant collagen research, with a comprehensive technology platform and a focus on high-quality product offerings [8] - The multi-dimensional product matrix of the company is expected to drive growth, with significant sales increases observed in July [8] - The company is projected to achieve substantial revenue and profit growth from 2025 to 2027, with corresponding price-to-earnings ratios indicating favorable valuation [8] Financial Forecasts - Revenue is forecasted to grow from 3,524 million RMB in 2023 to 10,206 million RMB in 2027, with a compound annual growth rate of approximately 20.17% [5] - Net profit is expected to increase from 1,452 million RMB in 2023 to 3,491 million RMB in 2027, reflecting a strong growth trajectory [5] - Earnings per share (EPS) is projected to rise from 1.49 RMB in 2023 to 3.26 RMB in 2027, indicating improved profitability [5] Market Performance - The company's products have shown resilience in the market, with significant growth in online sales channels, particularly during promotional events [8] - The company maintains a strong presence in both online and offline sales channels, with positive consumer feedback on its core products [8]

Group 1 - The Hong Kong stock market's new consumption concept stocks experienced a widespread decline, with notable drops in several companies [1] - Blucco (00325) saw a significant decrease of 8.27%, closing at 112.000 [2] - Other companies such as Laopu Gold (06181) and Pop Mart (09992) also faced declines of 3.44% and 2.32% respectively [2] Group 2 - Additional companies in the new consumption sector, including Qi (02517) and Weilon Delicious (09982), reported declines of 2.50% and 2.12% respectively [2] - Xpeng Motors (09868) and Li Auto (02015) experienced minor declines of 1.66% and 1.51% [2] - Other companies like Juzhi Biotechnology (02367) and Mijue Group (02097) also showed slight decreases, indicating a broader trend in the market [2]

Core Insights - The article discusses the competitive landscape and market dynamics of the functional skincare industry in China, highlighting key players, market share, and industry concentration levels [1][9][11]. Group 1: Brand Ranking - The functional skincare market in China is segmented into three main categories: dermatological skincare, strong efficacy skincare, and medical aesthetic skincare, with leading brands in each category [1]. - Notable brands in dermatological skincare include Winona, La Roche-Posay, and Avene; strong efficacy brands include WIS and HFP; medical aesthetic brands include Fulejia and Aimeike [1]. Group 2: Revenue and Market Position - The functional skincare industry is divided into three tiers based on revenue: - Tier 1: Betaini with revenue exceeding 5 billion CNY, leading the market [3][12]. - Tier 2: Companies like Giant Biological, Shanghai Jahwa, and Fulejia, which have significant revenue and brand recognition [3]. - Tier 3: Companies such as Proya and Furuida, which are publicly listed but have lower revenue from functional skincare [4]. Group 3: Market Share - The projected market size for functional skincare in China for 2024 is approximately 48.743 billion CNY, with Betaini holding a market share of 11.71% [9]. - Other significant players include Huaxi Biological at 5.27%, Fulejia at 4.14%, Shanghai Jahwa at 2.15%, and Giant Biological at 2.44% [9]. Group 4: Market Concentration - The market concentration for domestic functional skincare brands is relatively low, with the top three companies accounting for 21.12% of revenue and the top six for 26.47% [11]. - There is a trend of increasing market concentration, with leading players establishing brand and research barriers [11]. Group 5: Competitive Landscape - The industry shows a strong reliance on imported raw materials, with suppliers having significant bargaining power [16]. - Domestic brands are gaining market share, and competition is intensifying, with high profit margins and potential threats from new entrants and alternative products [16].

Core Insights - The global functional skincare market is projected to reach approximately $180.5 billion in 2024, with China accounting for about 27% of the global skincare market [6][8]. - The market for functional skincare products is expected to grow at a compound annual growth rate (CAGR) of 5%, potentially exceeding $240 billion by 2030 [10]. Industry Overview - The concept of "functional cosmetics" emerged in the 1940s, with the term "pharmaceutical cosmetics" introduced in the 1970s by dermatologist Albert Kligman, leading to widespread acceptance in Western countries [6]. - The functional skincare market is currently dominated by brands from Europe, Japan, and the United States, with significant players including L'Oréal, Estée Lauder, and Shiseido [3]. Market Competition - The global functional skincare market exhibits a moderate level of concentration, with numerous brands competing, although leading companies like L'Oréal and Estée Lauder hold significant market shares [4]. - China's Betaini has a notable competitive advantage in the dermatological skincare segment [3]. Future Projections - The global functional skincare market is expected to grow at a faster rate than the overall skincare market due to the increasing prevalence of sensitive skin issues in major countries [10].

Summary of Key Points Core Viewpoint - The investment and financing landscape of the medical beauty injection materials industry in China is relatively mature, with a significant number of investment events and a focus on scientific research and technology services. Group 1: Financing Status - As of June 2025, there have been 39 investment events in the medical beauty injection materials industry, indicating a mature investment environment [2][4]. - The majority of financing events are concentrated in Shandong and Jiangsu provinces, with Shandong having 8 events and Jiangsu 7 events [4]. Group 2: External Investment Layout - Representative companies in the medical beauty injection materials industry have engaged in numerous external investment events, primarily focusing on scientific research and technology services, which account for approximately 58% of their investments [14][13]. - Other sectors of investment include manufacturing (18%) and wholesale and retail (8%) [14]. Group 3: Mergers and Acquisitions - The level of mergers and acquisitions in the medical beauty injection materials industry is relatively low, with notable participation from real estate companies. For instance, Lushang Development acquired 100% of Shandong Furuida Pharmaceutical Group in 2018 to enter the medical beauty sector [16].

Key Points - The top three stocks with net inflows from southbound funds are Yingfu Fund (02800) with 1.184 billion, Alibaba-W (09988) with 730 million, and Hang Seng China Enterprises (02828) with 556 million [1] - The top three stocks with net outflows are WuXi Biologics (02269) with -539 million, Hua Hong Semiconductor (01347) with -509 million, and SMIC (00981) with -432 million [1] - In terms of net inflow ratio, Shanghai Industrial Holdings (00363) leads with 63.56%, followed by Bank of China Aviation Leasing (02588) with 60.26%, and Sunshine Insurance (06963) with 55.37% [1] - The top three stocks with the highest net outflow ratios are GX China (03040) at -100.00%, Southern Hang Seng Index ETF (03037) at -65.52%, and Sichuan Chengyu Expressway (00107) at -49.23% [1] Top 10 Net Inflows - Yingfu Fund (02800) had a net inflow of 1.184 billion, representing a 16.79% increase, closing at 25.380 [2] - Alibaba-W (09988) saw a net inflow of 730 million, with a 10.34% increase, closing at 116.300 [2] - Hang Seng China Enterprises (02828) had a net inflow of 556 million, with an 8.70% increase, closing at 91.160 [2] - Xiaomi Group-W (01810) had a net inflow of 473 million, with a 6.69% increase, closing at 51.250 [2] - Zai Ding Pharmaceutical (09688) had a net inflow of 429 million, with a 26.73% increase, closing at 27.200 [2] Top 10 Net Outflows - WuXi Biologics (02269) experienced a net outflow of -539 million, with a -33.02% decrease, closing at 29.360 [2] - Hua Hong Semiconductor (01347) had a net outflow of -509 million, with a -21.78% decrease, closing at 44.000 [2] - SMIC (00981) saw a net outflow of -432 million, with a -3.98% decrease, closing at 48.660 [2] - Kuaishou-W (01024) had a net outflow of -292 million, with a -14.76% decrease, closing at 79.150 [2] - Juzi Biotechnology (02367) experienced a net outflow of -220 million, with a -24.75% decrease, closing at 59.000 [2] Net Inflow Ratios - Shanghai Industrial Holdings (00363) had a net inflow ratio of 63.56%, with a net inflow of 11.36 million, closing at 14.870 [3] - Bank of China Aviation Leasing (02588) had a net inflow ratio of 60.26%, with a net inflow of 3.56 million, closing at 73.500 [3] - Sunshine Insurance (06963) had a net inflow ratio of 55.37%, with a net inflow of 2.48 million, closing at 3.790 [3] - Poly Property (06049) had a net inflow ratio of 52.60%, with a net inflow of 1.14 million, closing at 34.880 [3] Net Outflow Ratios - GX China (03040) had a net outflow ratio of -100.00%, with a net outflow of -7100.00, closing at 35.460 [3] - Southern Hang Seng Index ETF (03037) had a net outflow ratio of -65.52%, with a net outflow of -724,900, closing at 25.400 [3] - Sichuan Chengyu Expressway (00107) had a net outflow ratio of -49.23%, with a net outflow of -380,740, closing at 4.920 [3]

格隆汇8月12日丨巨子生物(02367.HK)公告，谨定于2025年8月27日(星期三)举行董事会会议，以考虑及 通过集团截至2025年6月30日止6个月中期业绩，及派发中期股息(如有)，以及处理其他事项。 ...

（於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 董事會會議召開日期 巨子生物控股有限公司（「本公司」及 其 附 屬 公 司「本集團」）董事會（「董事會」）兹 通告謹定於2025年8月27日（星 期 三）舉 行 董 事 會 會 議，以 考 慮 及 通 過 本 集 團 截 至 2025年6月30日 止 六 個 月 之 中 期 業 績，及 派 發 中 期 股 息（如 有），以 及 處 理 其 他 事 項。 承董事會命 巨子生物控股有限公司 董事會主席 GIANT BIOGENE HOLDING CO., LTD 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 巨子生物控股有限公司 嚴建亞 中 國 西 安，2025年8月12日 截至本公告日期，董事會成員包括執行董事嚴建亞先生、葉娟女士、方娟女士、 張 慧 娟 女 士 及 嚴 鈺 博 女 士 以 及 ...

Core Viewpoint - The company acknowledges limitations in its current testing methods for recombinant collagen products and outlines steps for improvement in response to industry and consumer demands [1][2]. Group 1: Company Response - The company has conducted a comprehensive self-inspection of its recombinant collagen raw materials and products, including production, testing, and labeling [1]. - It plans to collaborate with research institutions to optimize and validate qualitative and quantitative testing methods for recombinant collagen in cosmetics [1]. - The company will gradually disclose key technical parameters and quality control data for raw materials and finished products to enhance industry development and public oversight [1]. Group 2: Industry Standards and Practices - The company adheres to existing industry standards and has established its own quality control measures for raw materials and products [2]. - It is actively participating in the formulation of national and industry standards related to recombinant collagen in cosmetics to promote standardized development within the industry [1][2]. Group 3: Company Background and Market Performance - Founded in 2000, the company was listed on the Hong Kong Stock Exchange in 2022 and specializes in skin care products featuring recombinant collagen as a key active ingredient [2]. - The company's stock price has experienced significant fluctuations, with a decline of 37.12% from its peak of 87.1 HKD per share on May 20, 2025, to June 23, 2025 [2]. - Following the recent announcement, the stock price rose by 6.74% to 54.65 HKD per share as of June 24, 2025 [2].